|
Hypertensive disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Association of MYH9 Polymorphisms with Hypertension in Patients with Chronic Kidney Disease in China.
|
27924804 |
2016 |
|
Hypertensive disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
To better understand this, coding variants in the apolipoprotein L1 (APOL1) and the nonmuscle myosin heavy chain 9 (MYH9) genes were evaluated for an association with hypertension-attributed nephropathy and clinical outcomes in a case-control study.
|
22832513 |
2013 |
|
Hypertensive disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
A region of chromosome 22 which includes APOL1 and MYH9 genes was recently identified as a risk locus for non-diabetic forms of kidney disease, including idiopathic and HIV-associated focal segmental glomerular sclerosis and kidney disease clinically attributed to hypertension among African Americans.
|
22956460 |
2013 |
|
Hypertensive disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Mapping by admixture linkage disequilibrium (MALD; or admixture mapping) recently led to a major breakthrough in hypertension-attributed kidney disease in African Americans, demonstrating the role of the apolipoprotein L1 (APOL1) and nonmuscle myosin heavy chain 9 (MYH9) genes in this primary kidney disease residing in the spectrum of focal segmental glomerulosclerosis.
|
22614628 |
2012 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
BEFREE |
To narrow the region of association and identify potential causal variation, we performed a dense-mapping study using 79 MYH9 SNPs in AA populations with FSGS, HIVAN and H-ESKD (typed for a subset of 46 SNPs), for a total of 2496 cases and controls.
|
20124285 |
2010 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
BEFREE |
MYH9 will re-categorize focal segmental glomerulosclerosis and related disorders, and has clarified the relationship between hypertension and kidney disease.
|
19838113 |
2010 |
|
Hypertensive disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Risk variants in MYH9 likely contribute to the failure of hypertension control to slow progressive kidney disease in nondiabetic African Americans.
|
20051853 |
2010 |
|
Hypertensive disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
MYH9 risk variants appear to be associated with primary FSGS with secondary hypertension, although nephrosclerosis may develop in response to hypertension in subjects homozygous for the MYH9 E1 risk haplotype.
|
19153477 |
2009 |
|
Hypertensive disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Thus, hypertension-associated ESRD in African Americans is substantially related to MYH9 gene polymorphisms and this may explain the poor response to blood pressure control in those diagnosed with hypertensive nephrosclerosis.
|
19177153 |
2009 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Although MYH9 is strongly associated with biopsy-proven idiopathic and HIV-associated focal segmental glomerulosclerosis (FSGS) and clinically diagnosed 'hypertension-associated' end-stage renal disease (ESRD) in African Americans, its role in type 2 diabetes mellitus (T2DM)-associated ESRD is unclear.
|
19567477 |
2009 |
|
Hypertensive disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
These new data demonstrate that much of the excess risk of ESRD in African American individuals is attributable to an MYH9 risk haplotype and suggest that hypertension may cause progressive kidney disease only in genetically susceptible individuals or be the result of a primary renal disease.
|
18923054 |
2008 |
|
Hypertensive disease
|
0.200 |
GeneticVariation
|
group |
CLINVAR |
|
|
|